OmniAb (OABI) Research & Development (2022 - 2026)
OmniAb (OABI) reported Research & Development of $9.6 million for Q1 2026, down 23.5% year-over-year from $12.6 million in Q1 2025, and down 30.69% on a QoQ basis from $13.9 million in Q4 2025.
OmniAb (OABI) has 5 years of Research & Development data on file, last reported at $9.6 million in Q1 2026.
- Quarterly Research & Development fell 23.5% year-over-year to $9.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.8 million (down 15.74% YoY) and the FY2025 annual result came in at $47.8 million, down 13.35% from the prior year.
- Research & Development fell to $9.6 million in Q1 2026 per OABI's latest filing, from $13.9 million in the prior quarter.
- Across five years, Research & Development topped out at $14.8 million in Q4 2023 and bottomed at $9.6 million in Q1 2026.
- The 5-year median for Research & Development is $13.3 million (2024), against an average of $12.8 million.
- The widest annual swing landed in 2023, when Research & Development rose 27.73%; it then slipped 23.5% in 2026.
- Tracing OABI's Research & Development over 5 years: stood at $12.9 million in 2022, then gained by 14.3% to $14.8 million in 2023, then slipped by 9.89% to $13.3 million in 2024, then rose by 4.53% to $13.9 million in 2025, then slumped by 30.69% to $9.6 million in 2026.
- Per Business Quant, the three latest OABI Research & Development figures stand at $9.6 million (Q1 2026), $13.9 million (Q4 2025), and $10.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 9.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.64 Mn |
| Dec 31, 2025 | 13.91 Mn |
| Sep 30, 2025 | 10.38 Mn |
| Jun 30, 2025 | 10.86 Mn |
| Mar 31, 2025 | 12.60 Mn |
| Dec 31, 2024 | 13.31 Mn |
| Sep 30, 2024 | 13.32 Mn |
| Jun 30, 2024 | 13.94 Mn |
| Mar 31, 2024 | 14.55 Mn |
| Dec 31, 2023 | 14.77 Mn |
| Sep 30, 2023 | 13.87 Mn |
| Jun 30, 2023 | 14.13 Mn |
| Mar 31, 2023 | 13.76 Mn |
| Dec 31, 2022 | 12.92 Mn |
| Sep 30, 2022 | 13.19 Mn |
| Jun 30, 2022 | 11.48 Mn |
| Mar 31, 2022 | 10.77 Mn |